Related Experiment Videos
The emerging role of immunotoxins in leukemia and lymphoma
Abstract:
Despite important advances in conventional cancer therapy, there is still a strong need for new approaches in order to reduce cancer death rates, which have not been drastically influenced in the past ten years. Since minimal residual disease is regarded as the major cause for relapses of malignant diseases, immunotherapeutic strategies utilizing monoclonal antibodies (MoAbs) or their conjugates to target 'dormant' tumor cells have increasingly attracted scientific interest. Immunotoxins (ITs) constructed by chemically linking plant or bacterial toxins to a MoAb can selectively kill their target cells when internalized after binding to specific cell surface receptors. Many different ITs against various blood-borne as well as solid malignancies have been successfully tested in vitro and in animal models. Chemically linked ITs and recombinant fusion toxins generated by using DNA technologies are currently being evaluated for their antitumor activity in several clinical phase I/II/III trials. While serious side effects are rare, there are still many problems to be solved, such as the immunogenicity of the toxin and/or antibody moiety or the poor capacity of ITs to penetrate large solid tumors. At the moment only heavily pretreated patients with massive tumor burden are admitted to early clinical studies, so that even minor responses after IT treatment are encouraging. However, minimal residual disease is expected to be most amenable to IT therapy.
Insights
Immunotoxins (ITs) offer a novel cancer therapy approach by linking antibodies to toxins for targeted cell killing. These therapies show promise against minimal residual disease, a key factor in cancer relapse.
Area of Science:
- Oncology
- Immunology
- Biotechnology
Background:
- Conventional cancer therapies have limitations in reducing mortality rates.
- Minimal residual disease is a primary cause of cancer relapse.
- Targeting dormant tumor cells with immunotherapeutic strategies is gaining interest.
Purpose of the Study:
- To explore the potential of immunotoxins (ITs) as a novel cancer treatment.
- To evaluate the efficacy of ITs in targeting and eliminating cancer cells, particularly dormant ones.
- To discuss the current status and challenges of ITs in clinical trials.
Main Methods:
- Development of immunotoxins (ITs) by chemically linking monoclonal antibodies (MoAbs) to plant or bacterial toxins.
- Internalization of ITs into target cells after binding to specific cell surface receptors.
- Evaluation of ITs in vitro, animal models, and ongoing clinical trials (Phase I/II/III).
Main Results:
- ITs demonstrate selective killing of target cancer cells upon internalization.
- Various ITs have shown success against hematologic and solid malignancies in preclinical studies.
- Early clinical trials show encouraging responses, especially in heavily pretreated patients.
Conclusions:
- ITs represent a promising immunotherapeutic strategy for cancer treatment.
- Further research is needed to overcome challenges like immunogenicity and tumor penetration.
- IT therapy is particularly suited for targeting minimal residual disease to prevent relapse.